$-0.33 EPS Expected for Pacira Pharmaceuticals, Inc. (PCRX)
April 2, 2018 – By Maria Brooks
Investors sentiment increased to 1.4 in 2017 Q4. Its up 0.01, from 1.39 in 2017Q3. It is positive, as 29 investors sold Pacira Pharmaceuticals, Inc. shares while 41 reduced holdings. 31 funds opened positions while 67 raised stakes. 40.06 million shares or 3.76% less from 41.63 million shares in 2017Q3 were reported.
Great West Life Assurance Communications Can invested in 3,835 shares or 0% of the stock. Envestnet Asset Management Incorporated has 1,837 shares. 4,516 are held by Twin Focus Capital Ptnrs Limited Liability Co. Us Fincl Bank De has invested 0% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Point72 Asset Mgmt Limited Partnership holds 501,000 shares or 0.1% of its portfolio. 113,600 were accumulated by Utd Svcs Automobile Association. Principal Inc owns 11,236 shares. Nelson Van Denburg And Campbell Wealth Mngmt Grp Lc invested in 3,745 shares or 0.04% of the stock. New York-based Jpmorgan Chase has invested 0% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). California State Teachers Retirement invested in 0.01% or 61,947 shares. Avenir owns 15,870 shares. Cornerstone Cap Ltd Liability holds 0% or 11,700 shares in its portfolio. Schwab Charles Mngmt reported 187,249 shares or 0.01% of all its holdings. Geode Capital Ltd Limited Liability Company invested 0.01% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Northern Corp owns 489,753 shares.
Since December 15, 2017, it had 0 insider buys, and 2 insider sales for $1.18 million activity. On Friday, December 15 Riker Lauren Bullaro sold $14,858 worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) or 340 shares.
Analysts expect Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) to report $-0.33 EPS on May, 3.They anticipate $0.05 EPS change or 13.16 % from last quarter’s $-0.38 EPS. After having $0.18 EPS previously, Pacira Pharmaceuticals, Inc.’s analysts see -283.33 % EPS growth. The stock increased 0.65% or $0.2 during the last trading session, reaching $31.15. About 789,811 shares traded. Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has declined 33.05% since April 2, 2017 and is downtrending. It has underperformed by 44.60% the S&P500.
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Ratings Coverage
Among 16 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 8 have Buy rating, 1 Sell and 7 Hold. Therefore 50% are positive. Pacira Pharmaceuticals had 38 analyst reports since October 2, 2017 according to SRatingsIntel. Bank of America maintained the stock with “Buy” rating in Wednesday, October 4 report. H.C. Wainwright reinitiated it with “Buy” rating and $52 target in Thursday, November 9 report. RBC Capital Markets maintained the shares of PCRX in report on Wednesday, October 11 with “Buy” rating. Wedbush maintained Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) rating on Monday, November 20. Wedbush has “Buy” rating and $80.0 target. The rating was downgraded by Mizuho to “Neutral” on Wednesday, November 29. Canaccord Genuity maintained the shares of PCRX in report on Wednesday, November 8 with “Hold” rating. The rating was maintained by Seaport Global with “Buy” on Tuesday, March 20. The firm has “Hold” rating by J.P. Morgan given on Monday, December 18. H.C. Wainwright maintained Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) on Thursday, January 4 with “Buy” rating. The rating was maintained by Piper Jaffray on Wednesday, February 7 with “Buy”.
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company has market cap of $1.27 billion. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. It currently has negative earnings. The company's lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.